Gradinaru's group develops neurotechnologies - tissue clearing (CLARITY/PACT), engineered AAV gene-delivery vectors that cross the blood-brain barrier, optogenetic actuators/sensors, and light-sheet + single-molecule FISH imaging of cleared tissue - to map and manipulate neural circuits underlying neurodegeneration and behavior. For context, this complements the established paradigm of NV-diamond ensemble magnetometry (Hahn-echo/DEER, nanoscale NMR, T1 relaxometry) operating near pT/√Hz sensitivity.